About Precigen
Precigen is a company based in Germantown (United States) founded in 1998 by Thomas David Reed. Precigen has raised $233.76 million across 4 funding rounds. The company has 143 employees as of December 31, 2024. Precigen has completed 9 acquisitions, including ActoGeniX, EnviroFlight and Exemplar Genetics. Precigen offers products and services including PRGN-2012, Therapeutic Platforms, and Pipeline Therapies. Precigen operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Biogen, Alnylam and ATAI, among others.
- Headquarter Germantown, United States
- Employees 143 as on 31 Dec, 2024
- Founders Thomas David Reed
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Precigen, Inc.
-
Annual Revenue
$3.92 M (USD)-36.95as on Dec 31, 2024
-
Net Profit
-$126.23 M (USD)-31.63as on Dec 31, 2024
-
EBITDA
-$90.18 M (USD)-9.63as on Dec 31, 2024
-
Total Equity Funding
$233.76 M (USD)
in 4 rounds
-
Latest Funding Round
$13 M (USD), Post-IPO
Dec 17, 2020
-
Investors
Not available
-
Employee Count
143
as on Dec 31, 2024
-
Investments & Acquisitions
ActoGeniX
& 8 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Precigen
Precigen is a publicly listed company on the NASDAQ with ticker symbol PGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Precigen
Precigen offers a comprehensive portfolio of products and services, including PRGN-2012, Therapeutic Platforms, and Pipeline Therapies.
Gene therapy for treating recurrent respiratory papillomatosis in adults
Systems for gene expression in immuno-oncology applications
Advancing treatments for autoimmune and infectious diseases
People of Precigen
Unlock access to complete
Unlock access to complete
Funding Insights of Precigen
Precigen has successfully raised a total of $233.76M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $13 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Precigen
Precigen has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include ActoGeniX, EnviroFlight and Exemplar Genetics.
Investment portfolio details for Precigen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Waste is converted into protein-rich agri feedstock using insects.
|
Locked | Locked | 2009 | Locked | |
|
Genetic miniature pig models are developed for disease research.
|
Locked | Locked | 2008 | Locked | |
|
Antibody-based therapeutics are developed for biological targets.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Precigen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Precigen
Detailed financials for Precigen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Precigen Comparisons
Peer comparison for Precigen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Precigen
Precigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Biogen, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Precigen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Precigen
Complete news archive for Precigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precigen
Precigen was founded in 1998 and raised its 1st funding round 13 years after it was founded.
Precigen is headquartered in Germantown, United States.
Precigen is a funded company, having raised a total of $233.76M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Precigen is 143.
Annual revenue of Precigen is $3.92M as on Dec 31, 2024.
Precigen was founded in 1998 and is headquartered in Germantown, United States. Operations center on biopharmaceutical development of gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. A preclinical and clinical pipeline is progressed using non-viral and viral expression systems, along with genome editing, DNA and RNA engineering, and protein bioengineering. Precision technologies are applied to achieve on-target delivery and commercialization potential.
Precigen's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Precigen offers PRGN-2012, Therapeutic Platforms, and Pipeline Therapies.
Yes, Precigen is publicly traded on NASDAQ under the ticker symbol PGEN.
Precigen has made 9 acquisitions, including ActoGeniX, EnviroFlight, and Exemplar Genetics.
The ticker symbol of Precigen is PGEN on NASDAQ.